Antiviral Agents

Edited by
August 2020
386 pages
  • ISBN978-3-03928-953-0 (Hardback)
  • ISBN978-3-03928-954-7 (PDF)

This book is a reprint of the Special Issue Antiviral Agents that was published in

Biology & Life Sciences
Medicine & Pharmacology
Public Health & Healthcare
Antiviral agents are used for the treatment of viral diseases. Antiviral drugs have been successfully developed and used clinically for a limited number of important human viral diseases notably caused by human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), herpes, and influenza viruses. Despite the successes of these antiviral drugs, issues with drug resistance and toxicity remain challenging. These challenges are driving research to identify new drug candidates and to investigate novel drug targets to develop new mechanistic drug classes. Antiviral agents are not available against many viruses that cause human disease and economic burdens; in particular, the development of antiviral agents against emerging, re-emerging, and neglected viruses is increasingly becoming a priority. This book includes six review articles that discuss new antiviral strategies. The reviews either discuss advances relating to a specific virus or new therapeutic targets and approaches. The book includes 15 original research articles reporting new antiviral agents against a variety of clinically and economically important viruses and studies into the prevalence or acquisition of drug resistance. Overall, this book is an exciting collection of new research and ideas relating to the development of antiviral agents.
  • Hardback
License and Copyright
© 2020 by the authors; CC BY-NC-ND license
Zika virus; nucleoside analogues; antiviral agents; NS5; prodrugs; ProTides; neural stem cells; RNA-dependent RNA polymerase; cytomegalovirus; latent infection; TALEN; Surveyor nuclease mutation detection assay; ie-1 gene; quantitative real-time PCR; Epstein–Barr virus; herpes viruses; lytic gene expression; Burkitt lymphoma cells; clozapine; antipsychotic drug; antiviral drug; enteroviruses; coxsackievirus B4; persistent infection; fluoxetine; resistance; mutations; herpes B virus; macacine herpesvirus-1; genistein; flavonoids; acyclovir; ganciclovir; antiviral agents; Plantago asiatica; Clerodendrum trichotomum; RSV; therapeutic effects; acteoside; human antimicrobial peptides; antiviral strategies; defensins; cathelicidins; hepcidins; transferrins; influenza A virus; brevilin A; antiviral; sesquiterpene lactone; replication; PRRSV; polyethylenimine; PEI; virion internalization; antiviral; endocytosis; HIV; pediatrics; Ethiopia; pre-treatment drug resistance; combination antiretroviral therapy (cART); dried plasma spots; dried blood spots; sphingolipids; glycosphingolipids; viruses; lipid biosynthesis; antiviral; flavivirus; Zika virus; Japanese encephalitis virus; furin inhibitor; precursor membrane protein; measles virus; central nervous system; tropism; treatments; porcine reproductive and respiratory syndrome virus; ginsenoside Rg1; antiviral activity; pro-inflammatory factor; NF-κB signaling pathway; cytomegalovirus; acute/latent infection; congenital infection; antiviral agent; therapeutic strategies; nucleic acid-based therapeutic approach; HCMV vaccine; adoptive cell therapy; HIV; Rev response element; chemical footprinting; SHAPE; drug discovery; branched peptides; herpesvirus; cytomegalovirus; immediate-early; IE1; IE2; antiviral; ribozyme; RNA interference; CRISPR/Cas; small molecule; orthohantavirus; phenyl-benzotriazoles; antiviral activity; C-FRA; Porcine circovirus type 2; epigallocatechin gallate; heparan sulfate; antiviral effect; virus attachment; microvirin; lectin; human immunodeficiency virus; hepatitis C virus; antiviral inhibitor; non-immunogenic; viral entry; protein drugs; LUMS1; oleanane-type derivatives; influenza A virus (IAV); virus entry inhibitors; hemagglutinin (HA); n/a